Provided is a composition comprising a total dry weight of proteins and amino acids in of at least 80%; and wherein at least 95 wt % of said proteins have a mass of from about 70 to about 5,000 Daltons. Further provided is a growth medium comprising the composition, methods for the manufacture of the composition and uses thereof.

Herein is reported a method for obtaining a B-cell comprising the following steps a) labeling B-cells, b) depositing the labeled B-cells as single cells, c) co-cultivating the single cell deposited B-cells with feeder cells, d) selecting a B-cell proliferating and secreting IgG in step c) and thereby obtaining a B-cell. The labeling can be of IgG.sup.+CD19.sup.+-B-cells, IgG.sup.+CD38.sup.+-B-cells, IgG.sup.+CD268.sup.+-B-cells, IgG.sup.?CD138.sup.+-B-cells, CD27.sup.+CD138.sup.+-B-cells or CD3.sup.?CD27.sup.+-B-cells. The method can comprise the step of incubating said B-cells at 37? C. for one hour in EL-4 B5 medium prior to the depositing step. The method can also comprise the step of centrifuging said single cell deposited B-cells prior to the co-cultivation. In the co-cultivation a feeder mix comprising interleukin-1beta, and tumor necrosis factor alpha and Staphylococcus aureus strain Cowans cells or BAFF or interleukin-2 and/or interleukin-10 and/or interleukin-6 and/or interleukin-4 can be used.

Cell populations, compositions, and methods are provided relating to target priming of macrophage cells. The macrophages, once primed or activated with a microorganism, can be used to prevent or treat infection by the microorganism. Likewise, once primed or activated by a tumor cell or tumor antigen, the macrophage cell can be used to prevent or treat tumor of the same kind. The priming can be carried out in vitro or ex vivo. The macrophages can be isolated from the subject of disease prevention or treatment.

Disclosed are a Shewanella decolorationis producing tetrodotoxin and an application thereof, falling in the field of development and utilization of medicinal microorganisms. A strain, Shewanella decolorationis S3-4, is deposited in the China General Microbiological Culture Collection Center (CGMCC) on Mar. 28, 2022, with a deposit number of CGMCC No. 24602. The strain can secrete a same substance as tetrodotoxin from Tetraodontidae.

The invention relates to a dual-media approach for culturing isolated corneal endothelial cells. Isolated corneal endothelial cells are first contacted with a proliferative medium to propagate and/or expand the endothelial cells followed by a maintenance medium to preserve the morphology and/or characteristics of the corneal endothelial cells. The invention includes the proliferative medium and the maintenance medium and also a combination of the two medium.

A three dimensional in vitro co-culture system is provided for determining a pathogen's interaction with immune cells differentiated from healthy tissues and grown at air-liquid interface with epithelial cells. Also provided are methods of producing the three dimensional in vitro co-culture system. The system provides a way to assess predictive pathogenicity and threat, and develop medical countermeasures.

Disclosed herein is a Chlamydia-activated B cell (CAB) platform. Also disclosed is a method of enhancing a population of B cells, comprising exposing said B cells to Chlamydia spp. under conditions suitable to enhance the population of B cells, such that expansion and differentiation of said B cells takes place, and said B cells are exposed or crosslinked to an antigen. Also disclosed are methods of producing said CABs, and treating a subject in need thereof with said CABs.

A method for inhibiting xanthine oxidase and for reducing uric acid levels using a composition obtained by culturing Lactobacillus rhamnosus in a medium. Also disclosed is a composition including a metabolite of Lactobacillus rhamnosus for reducing uric acid levels in a subject and a method for producing the composition.

The present invention relates to a composition for maturing dendritic cells, comprising, as a maturation-promoting factor, Interleukin-1 (IL-1), Interleukin-6 (IL-6), Tumor necrosis factor- (TNF-), Interferon- (IFN-), Prostaglandin E2 (PGE2), Picibanil (OK432) and/or Poly IC. The composition for maturing dendritic cells of the present invention may have the effects of not only improving the ability of dendritic cells to induce an immune response, but also of decreasing the antigen non-specific immune response of dendritic cells and increasing antigen-specific immune response of dendritic cells, thus maximizing the effects of immunotherapy.

The present application relates to methods of activating a NK cells in vitro, ex vivo, and/or in vivo by an osteoclast cell (OC) and/or a dendritic cell, and methods of treating disease using these activated NK cells.